{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN7Z7u8JDA","lastupdate":"2023-06-16T00:00:00.000Z","update_date":"2023-06-16T00:00:00.000Z","lastModified":"Feb 26, 2025","active":1,"confidence_score":88,"confidence_score_reason":"video or image, funding rounds, markets, not claimed","urlname":"taro-pharmaceutical-industries","minimal_profile":null,"status":"Acquired","fullstatus":"Acquired by Sun Pharma on Jun, 2024","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$Q8m9BsUUHqutUA7RBUvmIR9ImevCZ0oEG5vj869zUarwynrtRc9SbO","name":"Taro Pharmaceutical Industries","oneliner":"Topical Pharmaceutical, Dermatological, and Cosmetic Products","registrar":"520022906","website":"https://www.taro.com","careerspage":"","founded_month":6,"founded_year":1959,"formernames":[],"sociallinks":{"twitter":"","youtube":"","facebook":"","linkedin":"https://www.linkedin.com/company/13778","instagram":""},"social":["https://www.linkedin.com/company/13778"],"flattenedsociallinks":"https://www.linkedin.com/company/13778","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":null,"employees":"500+","employees_exact":1344,"patent":1,"raised":0,"stage":"Acquired","public_stage":"Acquired","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":[""],"about":"Taro Pharmaceutical Industries is a research-based international pharmaceutical company manufacturing topical dermatological products and developing a line of solid drugs in cardiology and neurology.\r\nTaro synthesizes the active ingredients used in many of its key products. This vertical integration gives Taro control over the manufacturing and quality-control process from the active ingredients to the finished product and provides the company with a competitive advantage in the availability of quality raw materials, the reliability of supply, and the cost of active pharmaceutical ingredients.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+97248475700","country":null,"address":{"israeli":[{"id":"9ad9b0c0-ec5c-4b36-b582-ba68b4db6f58","city":"Haifa","type":null,"address":"HaKitor Street 14, Haifa, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":[{"id":"d9659f5e-54a7-4843-987c-7fb3f3d394e1","city":"Hawthorne","address":"3 Skyline Drive, Hawthorne, NY, USA","country":"United States","placeid":null},{"id":"e4b5e2eb-9683-4922-9a11-f54db3fb594b","city":"Brampton","address":"130 East Dr, Brampton, ON, Canada","country":"Canada","placeid":null}]},"headquarter_address":null,"district":"North District","news":[{"id":"sJh6SdmFSl9AxiCccAEIRWKB6sHKmDW0MTbJo3lAQH5M7Fn1A1Uy4D","date":"Jun 23, 2024","link":"https://www.prnewswire.com/news-releases/sun-pharma-completes-taro-merger-302180230.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"merger","company":"Sun Pharmaceutical Industries Limited","layoffs":null,"summary":"Sun Pharmaceutical Industries Limited announced the successful completion of its merger with Taro Pharmaceutical Industries Ltd. As part of this merger, Sun Pharma acquired all outstanding ordinary shares of Taro, making Taro a wholly-owned private subsidiary of Sun Pharma. This merger is expected to strengthen Sun Pharmas position in the competitive generics industry by leveraging the strengths and capabilities of both organizations. Sun Pharma is a leading specialty generics company with a significant presence in various global markets.","partners":null,"customers":null,"investors":[],"confidence":10,"key_topics":["merger","acquisition","generics","Taro","Sun Pharma"],"date_of_event":"Not specified","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Acquisition"],"acquisition_amount":null,"structuredIssuesShow":"#Acquisition","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"GmTnkkNDhas2J9EVHDLzTCKC7BACMXTOoRIeAshDA9vp9yYYtiPz5x","news_summary":"Sun Pharma Completes Taro Merger","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ZKr3IRWzBOGPj79QXKxcUJWCVND9DdAM2QLZPDkYlfb2259llaNrtY","date":"May 23, 2024","link":"https://www.prnewswire.com/news-releases/taro-shareholders-approve-merger-with-sun-pharma-302154180.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Merger, Approval","company":"Sun Pharmaceutical Industries Limited and Taro Pharmaceutical Industries Ltd.","layoffs":"N/A","summary":"Sun Pharmaceutical Industries Limited and Taro Pharmaceutical Industries Ltd. have announced that their merger agreement has been approved by Taro shareholders. The approval was given at an Extraordinary General Meeting and an Ordinary Class Meeting on May 22, 2024. The merger will enable Taro to merge with Sun and the combined entity will be able to better serve the needs of patients, healthcare professionals and customers globally. Upon completion of the merger, Taro will become a privately held company wholly owned by Sun Pharma and its shares will be de-listed from the NYSE.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":9,"key_topics":"Merger, Shareholder Approval, Delisting, Privatization","date_of_event":"May 22, 2024","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":"Acquired-by","acquisition_amount":"N/A","structuredIssuesShow":"#Acquired-by","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Obsirb4tg2VFy8WZxTVe3G1F3xzqR5LZt4W8nvrQp625MvBQZX8KG8","news_summary":"Taro Shareholders Approve Merger with Sun Pharma","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"l0fdgPw3LRIYmGC4AjoXs0vXfLfKrqyFA3dFYtY3KX9sPbIukOmuVX","date":"May 23, 2024","link":"https://finance.yahoo.com/news/taro-shareholders-approve-merger-sun-115000135.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Merger, Approval","company":"Sun Pharmaceutical Industries Limited, Taro Pharmaceutical Industries Ltd.","layoffs":"N/A","summary":"Sun Pharmaceutical Industries Limited and Taro Pharmaceutical Industries Ltd. have announced that their merger agreement has been approved by Taro shareholders. The approval was given at an Extraordinary General Meeting and an Ordinary Class Meeting on May 22, 2024. The merger will enable Taro to become a privately held company wholly owned by Sun Pharma and its shares will be de-listed from the NYSE. The merger is expected to close in approximately 35 days, subject to the satisfaction or waiver of certain closing conditions.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Merger Approval","Shareholders Vote","Company Delisting","Pharmaceutical Industry","Global Scale"],"date_of_event":"May 22, 2024","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Acquired-by"],"acquisition_amount":"N/A","structuredIssuesShow":"#Acquired-by","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"MlPeU46C3Wk4Gz3V9v8Rl2FgDcVozCP4eTPbwVSVlYyQl4YtVd5jCc","news_summary":"Taro Shareholders Approve Merger with Sun Pharma","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"SNo7mHav5FvNhNipMRlTQwjJgIYB3i61pVqmxuPu13SczQcnGEND3d","date":"May 20, 2024","link":"https://www.businesswire.com/news/home/20240520647281/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"0rHRWdBkFunDCgaf9YD9WKdQpHHYSfOoDEV3IWcyIGBlfFDHNSvcYk","news_summary":"Taro Provides Results for Year Ended March 31, 2024","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"2KKsMqNuvf7i2NEsAcxY05K5FJVqw1XYoQ8PV9ClHMiGcCdxaDpk5h","date":"May 8, 2024","link":"https://www.businesswire.com/news/home/20240508411736/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"3W4iTc35zPNFVeEQerzvXhdBmLdj1RYb5leOuDQLHjCoUDRP3XGmwU","news_summary":"Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Taro Shareholders Vote \"FOR\" Taro Sun Pharma Merger","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"RYnSVU6xhSRcm4aF1Cmgfdqj6psVK5pMCFLZK7R7MRhvw1vGP3JQJP","date":"Apr 14, 2024","link":"https://www.businesswire.com/news/home/20240412630482/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"Witqv4YR2LwlbjUyXienO72JuhDPaSqe0xKlMlh4Usxz8USWj5eICX","news_summary":"Taro Announces Extraordinary General Meeting and Ordinary Class Meeting of Shareholders for Approval of Merger with Sun Pharmaceutical Industries Ltd.","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"9AcKgZteqOBIerTIn4xssXFnpXdDKX3G1pRziNxM0nYbdOYLSdXc3F","date":"Mar 7, 2024","link":"https://finance.yahoo.com/news/chemical-linked-cancer-found-acne-143825624.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Product Safety, Health Risk","company":"Valisure LLC","layoffs":"N/A","summary":"Independent testing laboratory Valisure LLC has found high levels of benzene, a chemical linked to cancer, in acne treatments from brands including Proactiv, Target Corp.’s Up & Up, and Clinique. The lab has filed a petition with the US Food and Drug Administration (FDA) asking for a recall of the affected treatments. Over the past three years, benzene has been detected in several popular products, leading to recalls from companies including Johnson & Johnson, Unilever Plc, and Procter & Gamble Co. Valisure has positioned itself as a gatekeeper for consumers, conducting product research and testing drugs used by large health-care systems.","partners":"Kaiser Permanente, US Department of Defense","customers":"Proactiv, Target Corp.’s Up & Up, Clinique","investors":"N/A","confidence":9,"key_topics":["Benzene Contamination","Acne Treatments","Product Recall","FDA Investigation","Cancer Risk"],"date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Customers"],"acquisition_amount":"N/A","structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"tBEQXTbxDK0IzAU82z8AMEdBL3vSTrTtXzBuDRje9SnxaxeV9lHPAi","news_summary":"Chemical Linked to Cancer Found in Acne Creams Including Proactiv, Clearasil","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"3VMibEK5iJAjXISmk58uBll9EXZVokMw8i2uPlT2glV4qdNLTx8i33","date":"Jan 30, 2024","link":"https://www.prnewswire.com/news-releases/krensavage-asset-management-remains-opposed-to-suns-predatory-bid-for-taro-302047770.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Acquisition, Investment","company":"Taro Pharmaceutical Industries Ltd.","layoffs":"Not mentioned","summary":"Krensavage Asset Management, the largest minority shareholder of Taro Pharmaceutical Industries Ltd., has expressed its opposition to Sun Pharmaceutical Industries Ltd.s bid to take Taro private. Sun, a 78.5% Taro shareholder, increased its bid 13% to $43 a share, valuing Taro at $1.6 billion. However, Krensavage argues that this offer is inadequate, as it amounts to a 9% discount to the value of Taros tangible assets and fails to recognize Taros ability to generate cash.","partners":"Not mentioned","customers":"Not mentioned","investors":"Sun Pharmaceutical Industries Ltd.","confidence":8,"key_topics":["Acquisition Bid","Shareholder Opposition","Company Valuation","Cash Generation","Minority Shareholder"],"date_of_event":"Not specified","valuation_amount":"$1.6 billion","impact_on_company":"Growth-Negative","investment_amount":"Not mentioned","structured_issues":["Acquisition","Investment"],"acquisition_amount":"$1.6 billion","structuredIssuesShow":"#Acquisition  #Investment","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"Growth-Negative","analysisId":"lqGyUGnI2zPDoILQ2EeExZLB2htdVdKBU4wTH3zvgBzDWMPfwT4E0K","news_summary":"Krensavage Asset Management Remains Opposed to Sun's Predatory Bid for Taro","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"F2bN1ypdfuIg7dw8osDIxAzS0QsjKmMLkWbow5cm9GfBbGsCyVRZb7","date":"Jan 25, 2024","link":"https://www.businesswire.com/news/home/20240125784015/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"u77gH633AomMPJd3xxCd8KeSNdHxuzV0PopLxHyBDtJ4aUOvMbIVgj","news_summary":"Taro Provides Results for December 31, 2023","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"1ui3KHauG6hHQ6NZKZBaqInAs7DvaznuN9INYoQMK54BJXbu4mumxv","date":"Jan 17, 2024","link":"https://sg.finance.yahoo.com/news/indias-sun-pharma-buy-remaining-232534907.html","source":"sg.finance.yahoo.com","visible":1,"analysis":{"tags":"Acquisition","company":"Sun Pharmaceutical Industries Limited","layoffs":"N/A","summary":"Indias Sun Pharmaceutical Industries Limited has announced plans to acquire all remaining shares of Taro Pharmaceutical Industries, effectively taking full control of the unit. The deal, worth approximately $347.8 million, comes after nearly 17 years of negotiations. Upon completion of the merger, expected in the first half of the year, Taro will become a privately held company and will be delisted from the New York Stock Exchange.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Acquisition","Merger","Pharmaceuticals","Delisting","Price-fixing allegations"],"date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Acquisition"],"acquisition_amount":"$347.8 million","structuredIssuesShow":"#Acquisition","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"RYwXXPxQJGihuf9nRBVkuTBPhr1l3uXZZrBDZeLUmaPDBi5pNYyOOm","news_summary":"India's Sun Pharma to buy remaining stake in Israeli unit Taro for about $348 million","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"LFCKxHGZqHcRyNz2iGfZJ5XyR2keAOIEBPoDNzpA3Y8ILPPZV6Ph9y","date":"Jan 17, 2024","link":"https://www.prnewswire.com/news-releases/taro-announces-merger-agreement-with-sun-pharma-302037499.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Merger, Acquisition","company":"Sun Pharmaceutical Industries Limited and Taro Pharmaceutical Industries Ltd.","layoffs":"Not mentioned","summary":"Sun Pharmaceutical Industries Limited (Sun Pharma) and Taro Pharmaceutical Industries Ltd. (Taro) have announced a definitive merger agreement. Sun Pharma, Taros controlling shareholder, will acquire all of the outstanding ordinary shares of Taro not already held by Sun Pharma or its affiliates for US$43.00 per share in cash without interest. The purchase price represents a 48% premium over the closing price of US$28.97 per share on May 25, 2023. The merger is expected to close in the first half of 2024, at which point Taro will become a privately held company.","partners":"Not mentioned","customers":"Not mentioned","investors":"Sun Pharmaceutical Industries Limited","confidence":9,"key_topics":"Merger, Acquisition, Pharmaceuticals, Share Purchase, Company Valuation","date_of_event":"May 25, 2023","valuation_amount":"US$43.00 per share","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Acquisition","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Acquisition","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"yF0MBRO4DVJXm7j6919d3B5nIXyS7IjdK8SPOEyoq3ip34tdvbIUED","news_summary":"Taro Announces Merger Agreement with Sun Pharma","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"0g9dwSJEz0Cb1J8cFQGMSVKnQzpiEaciH0M5D1QNm14pnFLzIspnlx","date":"Jan 17, 2024","link":"https://finance.yahoo.com/news/taro-announces-merger-agreement-sun-213000607.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Merger, Acquisition","company":"Sun Pharmaceutical Industries Limited, Taro Pharmaceutical Industries Ltd.","layoffs":"Not mentioned","summary":"Sun Pharmaceutical Industries Limited (Sun Pharma) and Taro Pharmaceutical Industries Ltd. (Taro) have announced a definitive merger agreement. Sun Pharma, Taros controlling shareholder, will acquire all outstanding ordinary shares of Taro not already held by Sun Pharma or its affiliates for US$43.00 per share in cash without interest. The merger agreement was unanimously recommended by the Special Committee, formed by Taros Board of Directors to consider Sun Pharmas proposal. The merger is expected to close in the first half of 2024, after which Taro will become a privately held company and its shares will no longer be listed on the NYSE.","partners":"Not mentioned","customers":"Not mentioned","investors":"Sun Pharmaceutical Industries Limited","confidence":8,"key_topics":"Merger Agreement, Share Purchase, Company Acquisition, Shareholder Approval, Company Privatization","date_of_event":"Not mentioned","valuation_amount":"US$43.00 per share","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":"Acquisition, Management Changes","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Acquisition, Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"w0mLikm0zQKYwZTdZsO8ZGctCgGHFDjLSPV2NiEx82M0z7NjRiDJrP","news_summary":"Taro Announces Merger Agreement with Sun Pharma","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"VI0KDUvfqP0GvOreYskZyKOTBWvtmlbQqDQHJrYctrNoMiW9WbPZtk","date":"Dec 29, 2023","link":"https://finance.yahoo.com/news/amicus-fold-banks-galafold-overdependence-144800159.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Drug Approval, Sales Growth","company":"Amicus Therapeutics, Inc.","layoffs":"Not mentioned","summary":"Amicus Therapeutics lead drug, Galafold, has seen consistent sales growth, generating $281.2 million in the first nine months of 2023, a 16.6% YoY increase. The drug is approved in several countries, including the US, EU, UK, and Japan. In 2021, Galafold received label expansion in the EU for long-term treatment of adolescents with Fabry disease. In September 2023, the FDA approved Pombiliti + Opfolda, a therapy for treating late-onset Pompe disease. Global launches of these drugs are underway. However, Amicus heavy dependence on Galafold for revenues and competition from other pharmaceutical companies remain concerns.","partners":"Not mentioned","customers":"Patients with Fabry disease and Pompe disease","investors":"Zacks Investment Research","confidence":9,"key_topics":["Drug Approval","Sales Growth","Competition","Revenue Dependence","Label Expansion"],"date_of_event":"2023","valuation_amount":"Not mentioned","impact_on_company":"Growth-Positive","investment_amount":"Not mentioned","structured_issues":["Customers","Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"Pm9nV0Db4AVVi2zNcjF180VK8C7NLP9F50jSWwhMZlM6pzYdufClgQ","news_summary":"Amicus (FOLD) Banks on Galafold, Overdependence a Concern","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"Jy84LpHR72FqfYeoMgZPX6f5limpovybAMCKgZiodun4MQtg7snZum","date":"Dec 28, 2023","link":"https://finance.yahoo.com/news/iovance-iova-falls-clinical-lung-161300621.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Clinical hold, Adverse effect","company":"Iovance Biotherapeutics, Inc.","layoffs":"N/A","summary":"Shares of Iovance Biotherapeutics, Inc. fell by 18.7% on December 27, 2023, after the company announced a clinical hold on its phase II IOV-LUN-202 study. The study was evaluating LN-145 for treating patients with advanced non-small cell lung cancer (NSCLC). The hold was placed by the FDA following a fatal serious adverse effect potentially related to the non-myeloablative lymphodepletion pre-conditioning regimen observed in the study. As a result, the company will pause the enrollment of new patients in the study, which is likely to delay the clinical advancement of LN-145 in the NSCLC indication.","partners":"Merck","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Clinical hold","LN-145","NSCLC","FDA","lifileucel"],"date_of_event":"December 27, 2023","valuation_amount":"N/A","impact_on_company":"growth-negative","investment_amount":"N/A","structured_issues":["Management Changes"],"acquisition_amount":"N/A","structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"aC1xrCcSlyFPWXCWMHv8Ch6TBQPyUebmxjCf9y2mwVRbBQmdzFjHdL","news_summary":"Iovance (IOVA) Falls After Clinical Update on Lung Cancer Drug","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"KJUy8PrjGhpdMaNMUwxkIAe0VcKGo8Qh6tsqWk5kfaQNxUwjUB9mZI","date":"Dec 26, 2023","link":"https://finance.yahoo.com/news/cidara-cdtx-ec-nod-rezzayo-155100953.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Approval, Treatment, Partnership","company":"Cidara Therapeutics, Inc.","layoffs":"Not mentioned","summary":"Cidara Therapeutics has received approval from the European Commission for its treatment Rezzayo, used for invasive candidiasis. This approval has resulted in an 11.1% increase in the companys shares. This is the first new treatment option approved for this condition in over 15 years. The approval was based on data from the phase III ReSTORE study. Cidara has granted commercial rights to Rezzayo to Mundipharma in ex-U.S. markets and Japan. The approval is likely to trigger a milestone payment of around $11.14 million for Cidara from Mundipharma.","partners":"Mundipharma","customers":"Adult patients with invasive candidiasis","investors":"Mundipharma","confidence":9,"key_topics":["Drug Approval","Partnership","Investment","Stock Performance","Future Development"],"date_of_event":"December 22","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$11.14 million","structured_issues":["Customers","Partners","Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Customers  #Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"a5iWewtLpu5FrH26XlLfhiXJPVXijnBI25f8Rc2rOaBm4eCPL18I2h","news_summary":"Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive Candidiasis","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"G9cBUkDq4vqGl3SLVBkAkFZq7r2tki3CvGqiPyMODZ5jQpV2cVblqL","date":"Dec 26, 2023","link":"https://finance.yahoo.com/news/senti-bio-snti-rises-fda-163200480.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"FDA Approval, Clinical Trials","company":"Senti Biosciences, Inc.","layoffs":"Not Mentioned","summary":"Senti Biosciences, Inc. has received FDA clearance for its investigational new drug (IND) application to begin clinical studies on its CAR-NK cell therapy candidate, SENTI-202, for the treatment of relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML). The companys shares were up 18.7% following the announcement. The first patient in the study is expected to be treated in the second quarter of 2024. Senti Bio also has another cancer candidate in its portfolio, SENTI-301A, and has entered into a collaboration agreement with China-based biotechnology company, Celest Therapeutics.","partners":"Celest Therapeutics","customers":"Not Mentioned","investors":"Zacks Investment Research","confidence":9,"key_topics":["FDA Clearance","Clinical Studies","Cancer Treatment","Share Increase","Partnership"],"date_of_event":"December 22","valuation_amount":"Not Mentioned","impact_on_company":"Growth-Positive","investment_amount":"Not Mentioned","structured_issues":["Investment","Partners"],"acquisition_amount":"Not Mentioned","structuredIssuesShow":"#Investment  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"9Vc2aNphXR5ADKK7sp22ohn2ClbIl27Qjb5BAHBDOwAIfrL6fWz4CZ","news_summary":"Senti Bio (SNTI) Rises as FDA Clears IND for Cancer Candidate","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"wj2KX7Fz3IQibBuoFdsrwKWxQo1pl3bwkdvdtBTu3uFofPozPQ4cVu","date":"Dec 22, 2023","link":"https://finance.yahoo.com/news/sanofi-sny-discontinues-tusamitamab-ravtansine-150700518.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Cancer Research, Drug Development","company":"Sanofi","layoffs":"N/A","summary":"Sanofi has announced the discontinuation of its cancer program, tusamitamab ravtansine, following an interim analysis by an Independent Data Monitoring Committee (IDMC). The CARMEN-LC03 study, which investigated the antibody-drug conjugate as a monotherapy, failed to meet its dual primary endpoint of improving progression-free survival (PFS) versus docetaxel. Despite an improved overall survival trend, Sanofi decided to halt further clinical development of the drug due to non-improvement in PFS. The company will continue to explore the potential of tusamitamab-based antibody drug conjugates in other cancer indications.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":9,"key_topics":"Cancer Program, Drug Development, Study Results, Stock Performance, Healthcare Sector","date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"growth-negative","investment_amount":"N/A","structured_issues":"Management Changes","acquisition_amount":"N/A","structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"sJ5cG6SLlGO9czBTUEr4tUGYtj00JU5NQSTonbwcx6E4a1ZUGAVzyd","news_summary":"Sanofi (SNY) Discontinues Tusamitamab Ravtansine Cancer Program","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"UgTffAjx18NOD2SNQZ3fIAwC4WN8lbHuawcp5woH7A4TXgqrcKzGmr","date":"Oct 26, 2023","link":"https://www.businesswire.com/news/home/20231026372692/en/","source":"www.businesswire.com","visible":1,"analysis":null,"sentiment":null,"analysisId":"h36mOQv3mr73YdDs29e4wps1Lf6xXTPVqxtKjM7eTEKgi17NjJA2Ij","news_summary":"Taro Provides Results for September 30, 2023","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"none"},{"id":"bbJyWNLwDamv3agug3bxL4jZlHTRKUNqLBnVYkRWke9fN108FhX4Ub","date":"Jul 27, 2023","link":"https://www.businesswire.com/news/home/20230726580223/en/","source":"www.businesswire.com","visible":1,"analysis":{"tags":"Financial Report","company":"Taro Pharmaceutical Industries Ltd.","layoffs":"N/A","summary":"Taro Pharmaceutical Industries Ltd. has released its unaudited financial results for the quarter ended June 30, 2023. The company reported a net sales increase of $2.2 million, or 1.4%, to $158.9 million. Gross profit was $64.1 million compared to $81.6 million in the same period last year. Net income was $10.0 million compared to $14.1 million, resulting in earnings per share of $0.27 compared to net earnings per share of $0.37. Cash flow provided by operations for the quarter was $7.8 million.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Financial Results","Net Sales","Gross Profit","Net Income","Cash Flow"],"date_of_event":"July 27, 2023","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Customers"],"acquisition_amount":"N/A","structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ksGfhv7gcNRL7gWfN1YLwWLKtbtZgEP7rU2yAH5T8KY9OIWpfNQ9cu","news_summary":"Taro Provides Results for the Quarter Ended June 30, 2023","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"w52du4UWpmCnNNVYDIKAFEudoewJObNZsh3TvGlwqAshasFKlvEg26","date":"Jul 19, 2023","link":"https://www.prnewswire.com/news-releases/krensavage-asset-management-opposes-suns-lowball-bid-for-taro-301880370.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Acquisition, Shareholder Disagreement","company":"Taro Pharmaceutical Industries Ltd.","layoffs":"N/A","summary":"Krensavage Asset Management, the largest minority shareholder of Taro Pharmaceutical Industries, has opposed the bid by Sun Pharmaceutical Industries to take Taro private. Sun, which owns 78.5% of Taro, offered to acquire the rest of Taro for $38 a share, valuing the company at $1.4 billion. Krensavage argues that this offer is inadequate and amounts to a 17% discount to the value of Taros tangible assets. The firm also criticises Sun for failing to offer a control premium and for ignoring Taros 22 generic drugs awaiting clearance in the U.S.","partners":"N/A","customers":"N/A","investors":"Sun Pharmaceutical Industries Ltd.","confidence":9,"key_topics":["Acquisition Offer","Shareholder Opposition","Company Valuation","Generic Drugs","Previous Bids"],"date_of_event":"May 26","valuation_amount":"$1.4 billion","impact_on_company":"growth-negative","investment_amount":"N/A","structured_issues":["Acquisition"],"acquisition_amount":"$38 per share","structuredIssuesShow":"#Acquisition","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"1obNrpQLZfFVgbmfSOtzDvmaF6bcOemqQpAIvDRf0lO5BUR5AjJ0c7","news_summary":"Krensavage Asset Management Opposes Sun's Lowball Bid for Taro","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"de2UCcZmj070AMMt4BflvwbkLpFHDrXD2G9mB0Kw25VJCYlK93dmQK","date":"Jun 30, 2023","link":"https://www.businesswire.com/news/home/20230630387986/en/","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"vhmwDOS8XKDdeAjdYewmIiWyRlnt5fNYt7yxOmxjrgFIwnbWdUlt4F","news_summary":"Taro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2023","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"FFPeFhCuOf8hNp7spuyFYk6ed8hRgp3UUbeJ4oRNxnjAAUf5ElFiH0","date":"May 30, 2023","link":"https://en.globes.co.il/en/article-sun-offers-to-buy-100-stake-in-taro-pharmaceuticals-1001448012","source":"en.globes.co.il","visible":1,"analysis":{"tags":"acquisition","company":"Sun Pharmaceuticals","layoffs":null,"summary":"Sun Pharmaceuticals, an Indian company, has made an offer to purchase all the shares of Taro Pharmaceutical Industries, an Israeli company, at a 30% premium. Taros share price jumped by 22.66% in afterhours trading following the offer. Suns offer reflects a company value of $1.4 billion. Taros board of directors has set up a special independent committee to examine the offer. Taros share price has been declining in recent years and is currently 80% below its peak in 2015. Sun Pharmaceuticals is seeking to delist Taro from Wall Street.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["Sun Pharmaceuticals","Taro Pharmaceutical Industries","offer","share price","market cap"],"date_of_event":"May 30, 2023","valuation_amount":"$1.4 billion","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Acquisition"],"acquisition_amount":null,"structuredIssuesShow":"#Acquisition","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"cI4abgqzBqTLCu6ziu52GrhZByJyeXeGgMXjl3twR7wIdFiONVciBp","news_summary":"Sun offers to buy 100% stake in Taro Pharmaceuticals","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"2kJzbtBzSEuYid6dlzNF2fHLUFb4GH9gIikhaXgHCxqD1v8DB1eP6A","date":"May 30, 2023","link":"https://finance.yahoo.com/m/9c06d39d-9f4c-3af0-a656-455a455a379b/why-shares-of-taro.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"buyout offer","company":"Taro Pharmaceutical Industries","layoffs":null,"summary":"Shares of Taro Pharmaceutical Industries rose over 23% after the company received a buyout offer from Sun Pharmaceuticals. Sun Pharmaceuticals plans to buy the remaining 21.5% of Taros shares at $38 per share, at a premium of 31.2% over the stocks closing price. Taros directors support the move, stating that it would benefit all shareholders.","partners":null,"customers":null,"investors":"Sun Pharmaceuticals","confidence":9,"key_topics":["Taro Pharmaceutical","Sun Pharmaceuticals","buyout offer","SEC filing","shareholders"],"date_of_event":"May 25","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Acquisition"],"acquisition_amount":null,"structuredIssuesShow":"#Acquisition","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"84lm7XxXJFI4H7eAMhQYYGFueghe4aoVa3J3RrykUQWvbO4vWpKSSH","news_summary":"Why Shares of Taro Pharmaceutical Are Rising Tuesday","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"oIxbrx880S1jvHEl7z2RZh6mZeLpZ3VeJkUqTQ8lS3DogyS5WQ91Gd","date":"May 23, 2023","link":"https://www.businesswire.com/news/home/20230523006054/en/","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"GNBli6LXBqAAm3NPq9shcUoARS1u5C1KyeFLG565wUP0o9hBrWBIeM","news_summary":"Taro Provides Results for Year Ended March 31, 2023","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"tO9dC6TNv1HIONBdy5x22T4wY5vPplI5Kq4tCj0eERRjcQBlrqB7IE","date":"Apr 17, 2023","link":"https://finance.yahoo.com/news/past-five-years-taro-pharmaceutical-173524219.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"TFcVrfh9NrvjAZ2yx7nzceETb5lTet1j09gVFMUl8dItvqcIFtV7iB","news_summary":"The past five years for Taro Pharmaceutical Industries (NYSE:TARO) investors has not been profitable","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"crWm5oIMb6kNMHphluu5cRrYhYVLyonFHVICZrUcGZROYLj88FFJSh","date":"Jan 27, 2023","link":"https://finance.yahoo.com/news/taro-pharmaceutical-industries-third-quarter-110136607.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"4ylP7KNC7a91lacVDP9c3PsAFoC8HypRz2gebOAHaa4dLH05vxncWL","news_summary":"Taro Pharmaceutical Industries Third Quarter 2023 Earnings: Misses Expectations","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"XpTO23SYDMlUzm1okgUkhnxkF9iaXlZ6vI0CjWiQeN8qUpfegbkVkA","date":"Jan 24, 2023","link":"https://www.businesswire.com/news/home/20230124006013/en/","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"slSWzt3BBjQYz72y40GNdXMPnBxhxxnxg8KmhP6MyIhqiq4yjOvH1V","news_summary":"Taro Provides Results for December 31, 2022","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"TMfIvoLI84uAdYYnyFRNtts57oa2QJJpWPgEtRktuByPrX63WIkHnt","date":"Jan 19, 2023","link":"https://www.businesswire.com/news/home/20230119005893/en/","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"ZOuHkME3QP9FrsI2vczxJi8DQsuGFJCae3MED8oUekLQ2jBNsaxDNl","news_summary":"Taro to Release Third Quarter Results on January 24, 2023","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"wFf9IbPAEugBesz0DDypcD1gCmRuIlpXtXhMabncheJnEMNebOQTH1","date":"Oct 27, 2022","link":"https://finance.yahoo.com/news/taro-pharmaceutical-taro-reports-q2-235511639.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Earnings Report, Stock Performance","company":"Taro Pharmaceutical","layoffs":null,"summary":"Taro Pharmaceutical reported a quarterly loss of $0.07 per share, compared to the Zacks Consensus Estimate of $0.84 and earnings of $0.66 per share a year ago. The companys revenues for the quarter ended September 2022 were $130.5 million, missing the Zacks Consensus Estimate by 18.96%. This compares to year-ago revenues of $131.99 million. Taros shares have lost about 34.4% since the beginning of the year. The companys future performance will depend on managements commentary on the earnings call and earnings outlook.","partners":[],"customers":[],"investors":[],"confidence":9,"key_topics":["Quarterly Loss","Revenue Miss","Stock Decline","Earnings Outlook","Industry Performance"],"date_of_event":"Quarter ended September 2022","valuation_amount":null,"impact_on_company":"Growth-Negative","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"Growth-Negative","analysisId":"Z0viziDBxqkSV5PUcy2L3zo2CAAaFrQsP9z1g3rwZISA3WQKImEVwA","news_summary":"Taro Pharmaceutical (TARO) Reports Q2 Loss, Misses Revenue Estimates","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"qNf3rAROmgi2PQVHLQ9ufpDjmC3SONdplrT4Hsw4zWpdx2f1b2hxXv","date":"Oct 27, 2022","link":"https://www.businesswire.com/news/home/20221027006161/en/","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"udnZaUhyTflyAk8VJpyTUEotsIlcW97FyXTCmmQE5YAP0bcinDOqkp","news_summary":"Taro Provides Results for September 30, 2022","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"CS8ukomNRgM3QFKYBVO9wK6KFJNtN0cHBxvOt5RVy4ONGPkVJSs3Pk","date":"Oct 24, 2022","link":"https://www.businesswire.com/news/home/20221024005697/en/","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"Wj1sSkaEX80ZFh29SPjjHIxaB9MBjywvknIxj70XDzUxbwMmWiMwPP","news_summary":"Taro to Release Second Quarter Results on October 27, 2022","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"ee85hdlvrmFMdFOhFwnsFxgOidDqEqFtks38gnmHZBT9dID5qduYFQ","date":"Oct 12, 2022","link":"https://finance.yahoo.com/news/five-shareholder-returns-company-earnings-145845127.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"wTfOMYcp5hJL32kRd3zaettVRBgP9ijhN3DDigrUP32iBaDCpltwYB","news_summary":"The five-year shareholder returns and company earnings persist lower as Taro Pharmaceutical Industries (NYSE:TARO) stock falls a further 8.9% in past week","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"QAVzn4cpL9nUcidTQYV2G9WRK0zoi6NY7FXo81UhcPdkaEbjtpYqUh","date":"Aug 11, 2022","link":"https://www.businesswire.com/news/home/20220810005801/en/","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"JUqWtKHa6BL3hWCP10ai6qYlyL8PVx89rz9ejmGr9LRq4d0Uc7d8AB","news_summary":"Taro Pharmaceuticals Inc. Issues Voluntary Type I Recall of Taro-Zoledronic Acid Injection, 5 mg/100 mL, 100 mL Vial Due to Particulate Matter Over Specified Requirements","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"mAeH5zJjYvkv5j8io8bnAldb5k0vdDqNupPihOJxQS0UllWHc5oQUJ","date":"Jul 27, 2022","link":"https://finance.yahoo.com/news/taro-pharmaceutical-taro-lags-q1-230511737.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"JJjW7ARFqV4JE9msL0GQeOGQSixbUmSsUxCHMr0oIIyE9WgAchBu2D","news_summary":"Taro Pharmaceutical (TARO) Lags Q1 Earnings Estimates","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"L4jIYCLGULW588DjtJ8zVHcdDHxZtt8BvCODyjcu7Rr0WKqRlb147p","date":"Jul 27, 2022","link":"https://www.businesswire.com/news/home/20220727005946/en/","source":"www.businesswire.com","visible":1,"analysis":{"tags":"Financial Results, Acquisition","company":"Taro Pharmaceutical Industries Ltd.","layoffs":"N/A","summary":"Taro Pharmaceutical Industries Ltd. has released its unaudited financial results for the quarter ended June 30, 2022. The company reported net sales of $156.7 million, an increase of $9.6 million or 6.5% compared to the same period in 2021. Operating income was $14.0 million compared to an operating loss of $(19.2) million in the previous year. The company also reported a net income of $14.1 million compared to a net loss of $(18.8) million in 2021. The companys CEO, Uday Baldota, acknowledged the challenges of price deflation and rising input costs, but affirmed the companys commitment to growth and profitability.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Financial Results","Acquisition","FDA Approvals","Antitrust Litigation","Market Challenges"],"date_of_event":"July 27, 2022","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Acquisition"],"acquisition_amount":"N/A","structuredIssuesShow":"#Acquisition","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"CzSFbgSZSa0bINSqOiQe7X5eITsl41QwKWjBY96XzB5dhbozOg54S8","news_summary":"Taro Provides Results for the Quarter Ended June 30, 2022","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"TVlWPToLOeVZxp77drKFNoJUe8XQQT6ebmf9vNLj3stZcKmVIXwb5x","date":"Jul 26, 2022","link":"https://www.businesswire.com/news/home/20220726006021/en/","source":"www.businesswire.com","visible":1,"analysis":{"tags":"Financial Results","company":"Taro Pharmaceutical Industries Ltd.","layoffs":"Not mentioned","summary":"Taro Pharmaceutical Industries Ltd. has announced that it will release its financial results for the first quarter ended June 30, 2022, after the close of market on Wednesday, July 27, 2022. The release will be accessible on Taro’s website.","partners":"Not mentioned","customers":"Not mentioned","investors":[],"confidence":10,"key_topics":["Financial Results","Quarterly Report"],"date_of_event":"July 26, 2022","valuation_amount":"Not mentioned","impact_on_company":"Neutral","investment_amount":"Not mentioned","structured_issues":[],"acquisition_amount":"Not mentioned","entityGrowthIconPath":"none;"},"sentiment":"Neutral","analysisId":"qMMiEvKDKRkAgronRTxvCOHm8RSBB9fkVJjjbWU56zUdqWZMsleiCq","news_summary":"Taro to Release First Quarter Results on July 27, 2022","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"dJoJxVoiDEj8KLNDiTnVb4cGfSCIiGcITdgIKhcQs8zPdUk5RZwwaJ","date":"Jul 26, 2022","link":"https://www.businesswire.com/news/home/20220726006103/en/","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"uRgvgNglbnTXZPtCEM1d7pMMGZ8ObXchbzvd28mmciRov6I2aFdf9M","news_summary":"Taro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2022","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"449c7186-60e5-4c08-bff9-10babcd8dadf","date":"Jun 17, 2020","link":"https://www.prnewswire.com/news-releases/ntc-grants-license-and-distribution-rights-in-israel-to-taro-pharmaceutical-industries-for-its-fixed-combination-of-an-ophthalmic-quinolone-antibiotic-with-an-anti-inflammatory-steroid-301076661.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"partnership","company":"NTC Srl","layoffs":null,"summary":"NTC Srl, an Italian pharmaceutical company, has granted exclusive license and distribution rights for its research and development product to Taro Pharmaceutical Industries in Israel. The product is a fixed combination in eye drops aimed at providing treatment for post-cataract surgery. NTC completed an international clinical study to support the products efficacy. This partnership with Taro is a significant achievement for NTC and demonstrates their commitment to the ophthalmology field. The product has been partnered and out-licensed by NTC to 60 countries worldwide. NTC is a pharmaceutical company engaged in research, development, and commercialization of drugs and medical devices. Taro Pharmaceutical Industries is a multinational pharmaceutical company dedicated to meeting customer needs through high-quality healthcare products.","partners":["Taro Pharmaceutical Industries"],"customers":null,"investors":null,"confidence":9,"key_topics":["license","distribution","eye drops","post-cataract surgery","international partnership"],"date_of_event":"June 17, 2020","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"4H6m9OuAvjFprXJQMs2uNCvEQ2az6FNe1v21oAAiCcCuUcPOiypJyW","news_summary":"NTC Grants License and Distribution Rights in Israel to Taro Pharmaceutical Industries, for Its Fixed Combination of an Ophthalmic Quinolone Antibiotic With an Anti-inflammatory Steroid","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"0bf93d9a-614d-4142-8257-0ae0d34659f9","date":"Aug 8, 2019","link":"https://www.businesswire.com/news/home/20190808005909/en/Taro-Results-Quarter-Ended-June-30-2019","source":"www.businesswire.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"2Osxcc423KPcgYIorHxbl2norRnuDhsfe3xOv088yR8T0wpF2NpQ13","news_summary":"Taro Provides Results for Quarter Ended June 30, 2019","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"b9ec620b-7ec0-4641-a75b-b8d00c2b967a","date":"Dec 17, 2018","link":"https://www.prnewswire.com/news-releases/us-fda-approves-removal-of-not-for-home-use-label-restriction-for-pliaglis-300767315.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"FDA Approval, Partnership","company":"Crescita Therapeutics Inc.","layoffs":"N/A","summary":"Crescita Therapeutics Inc., a Canadian commercial dermatology company, has announced that the U.S. Food and Drug Administration (FDA) has approved the Prior Approval Supplement (PAS) for Pliaglis. The approval follows a six-month review process. In 2017, Taro Pharmaceuticals Inc., Crescitas licensee for Pliaglis in the U.S. market, completed a study to support the removal of the Pliaglis Not for Home Use label restriction. The approval of this submission triggers a milestone of US$0.5 million for Crescita. The label change will expand the ability of patients to have access to the drug and will facilitate Taros efforts to increase market acceptance of Pliaglis in the U.S.","partners":"Taro Pharmaceuticals Inc.","customers":"Patients","investors":"N/A","confidence":9,"key_topics":["FDA Approval","Pliaglis","Partnership","Label Change","Market Expansion"],"date_of_event":"Dec. 17, 2018","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Partners","Customers"],"acquisition_amount":"N/A","structuredIssuesShow":"#Partners  #Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"fqPrbHsg8esJgpN6Q6Ccjfdbf24eeOL3sZgywsfUDH61HHYpwbpZrI","news_summary":"U.S. FDA Approves Removal of \"Not for Home Use\" Label Restriction for Pliaglis®","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"1d6ebc10-1850-4e8a-9e52-ebaa74a23d14","date":"Aug 15, 2014","link":"http://www.haaretz.com/business/.premium-1.610572","source":"www.haaretz.com","visible":1,"analysis":{"tags":["pharmaceuticals"],"company":"Taro Pharmaceutical Industries","layoffs":null,"summary":"Taro Pharmaceutical Industries reported a decline in sales and gross profits, but its stock price still rose. The company, which was on the verge of liquidation in 2007, is now worth $6.3 billion. Taros revival can be attributed to its acquisition by Sun Pharma, which injected $40 million into the company. Taro has been able to raise prices on its drugs, particularly in the skin medication market, due to its dominating influence in the niche and limited competition. The companys financial results were impacted by provisions for discounts to its largest customers. Taros ability to raise prices has contributed to its profitability and attracted the attention of Teva, which aims to gain a bigger foothold in the skin medication market.","partners":null,"customers":null,"investors":"Sun Pharma","confidence":8,"key_topics":["sales decline","stock price increase","financial results","price increases","skin medication market"],"date_of_event":null,"valuation_amount":"$6.3 billion","impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"pwhgCJp1clwRLWBaDgrPrPAVaDvvfuh3Q6xWb6sdpPjoVtq3coWb17","news_summary":"Taro Pharmaceuticals, once nearly broke, now has $6 billion market cap","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":42,"techcommunityinvolvement":null,"mediagallery":[],"tags":["pharmaceuticals","manufacturing","healthcare-providers","topical-treatment","cardiovascular","oral-drugs","pediatrics","drug-discovery","hospitals","dermatology","anti-inflammatory","treatments"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuMqZMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B"],"productstage":"Released","products":[],"geomarkets":["United States","Global","Israel","Canada"],"targetmarkets":[],"marketcapital":1277876352,"marketcapitaldate":"2023-11-01T14:01:13.000Z","funding":{"investors":0,"lastfunding":"Undisclosed","totalrounds":1,"fundingstage":"Acquired","totalfunding":"Undisclosed","publicinvestors":0,"lastpublicfunding":0,"totalpublicrounds":1,"totalpublicfunding":0},"team":[{"name":"Uday Baldota","email":"uday.baldota@sunpharma.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoOn-1c8IDA","bounced":false,"claimed":0,"founder":0,"urlname":"uday-baldota","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICg6YLR6QsM","position":"CEO","last_name":"Baldota","claimtoken":"h67wc6BzmbHBQwzDBF37GK7RNhfQw9iE8fjC3c1pMq1BBVHet7FhJY","first_name":"Uday","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/udaybaldota/","unsubscribed":true,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2023-06-16 13:54:48.000000","initials":"UB","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Michael Perfetto","email":"michael.perfetto@taro.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoKmd04MLDA","bounced":false,"claimed":0,"founder":0,"urlname":"michael-perfetto","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICg6cSnqQgM","position":"CCO","last_name":"Perfetto","claimtoken":"4F8cTn3DPynsR8b47cLbtcS0JuxS76BWhSnLrgcvi0hYSeDhVMPxQi","first_name":"Michael","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/michael-perfetto-1a82294/","unsubscribed":true,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2023-06-16 13:55:10.000000","initials":"MP","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Avi Avramoff","email":"avi.avramoff@taro.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoOmksIQLDA","bounced":false,"claimed":0,"founder":0,"urlname":"avi-avramoff","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICgqdOlkQsM","position":"Global VP R&D","last_name":"Avramoff","claimtoken":"RAaxtC1vRuQmfERzeGXq7dsUPBBO4lDMkayoaXZW5Q75U0PesBFvAx","first_name":"Avi","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/avi-avramoff-r-ph-ph-d-6b1351/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2023-06-16 13:55:08.000000","initials":"AA","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Michele Visosky","email":"michele.visosky@taro.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoOnQxuALDA","bounced":false,"claimed":0,"founder":0,"urlname":"michele-visosky","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICg6d7cnggM","position":"Group VP Human Resources","last_name":"Visosky","claimtoken":"CRJ0mf6jwMvM7K5ZJTmr7e4s9mrbasvL5GpPVvO8utZrrkhYiuqldQ","first_name":"Michele","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/michele-visosky-36524940/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2023-06-16 13:55:25.000000","initials":"MV","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Barbara Pimentel","email":"barbara.pimentel@taro.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoOmC0ekKDA","bounced":false,"claimed":0,"founder":0,"urlname":"barbara-pimentel","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICgqd2YiwsM","position":"VP Sales & Marketing","last_name":"Pimentel","claimtoken":"EYjwhCUfCeMYW97pGfgpb3Iyop8RsKtzuT0XKenphgZyvlHKKn7xwx","first_name":"Barbara","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/barbara-pimentel-7186781b/","unsubscribed":true,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2023-06-16 13:55:34.000000","initials":"BP","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Andreas Wegner","email":"andreas.wegner@taro.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoOnEp8kLDA","bounced":false,"claimed":0,"founder":0,"urlname":"andreas-wegner","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICg6cLDqwsM","position":"VP, Head of Manufacturing ","last_name":"Wegner","claimtoken":"DJMhd3Jo0OerOLRAVmyCXdUffwGGEsrl1zd4FFe30QIohdiSFUppHk","first_name":"Andreas","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/andreas-wegner-b064097/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2023-06-16 13:55:37.000000","initials":"AW","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Pharmaceuticals","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgPGylJ0IDA","fullname":"Natalia Golczar"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgPGylJ0IDA","fullname":"Natalia Golczar"},"biverifydate":"2019-09-25T00:00:00.000Z","crunchbaseid":"taro-pharmaceuticals","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wainscheinker@sncentral.org","creator":null,"creator_email":null,"createdate":"2015-02-17T00:00:00.000Z","biverification":"Natalia Golczar","sectorverification":"Natalia Golczar","affiliatedOrganizations":null,"timeline":[{"id":"Skiy65EIIbq3nXz5QzoSWnmUMPZVkdwq5NDzpFMsX1XPwvLMsujpUk","date":"Jun 2024","amount":"Undisclosed","source":"https://www.prnewswire.com/news-releases/sun-pharma-completes-taro-merger-302180230.html","ticker":null,"eventtype":"DelistingEvent","valuation":"Undisclosed","investment":[],"capitalraised":"Undisclosed","stockexchange":"NYSE","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODIgdygCww","stockexchange_logokey":"$gCUzHIIl5WdaUySSBVfr4ukCJPjuwKJMFXjiY09JCLUNERZRom14T0","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$gCUzHIIl5WdaUySSBVfr4ukCJPjuwKJMFXjiY09JCLUNERZRom14T0","exit_label":"","po_label":"Public Offering","duetoacquisition":"","isdelisting":1,"acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":null,"valuationnumber":null},{"id":"t5XlZkxlKsdKG69lELpobxtXJkc3eZIOPqlbsp488dRcWVjFFWOVtt","date":"Jun 2024","amount":"$348M","source":"https://www.business-standard.com/companies/news/sun-pharma-completes-taro-merger-acquires-all-outstanding-shares-124062400760_1.html","mnatype":"Merger","eventtype":"MNAEvent","investment":[],"wasacquired":1,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"Sun Pharma","acquiredcompany_mna_id":"HVHnVuoITlgYVXrTjJQpobCM6Z1ranbHPiJvPmRUMvaorlr2mB5Nxx","acquiredcompany_mna_type":"Multinational","acquiredcompany_mna_hidden":true,"acquiredcompany_mna_fullurl":"/mnc_page/sun-pharma","acquiredcompany_mna_logokey":"$f7bQHJVgU2m3GYrQtggBQn8TSKqZRkYVVpj9sD2uOcMRUcvOZtzvcN.png","acquiredcompany_mna_urlname":"/mnc_page/sun-pharma","acquiredcompany_mna_homepage":"http://sunpharma.com","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$f7bQHJVgU2m3GYrQtggBQn8TSKqZRkYVVpj9sD2uOcMRUcvOZtzvcN.png","exit_label":"","po_label":"Public Offering","acquireddesc":"Merged to","sectionname":"Public Offerings & Exit","amountnumber":348000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCI2vajCAw","date":"Mar 2012","amount":"Undisclosed","source":"","ticker":"TARO","eventtype":"POEvent","valuation":"Undisclosed","investment":[],"capitalraised":"Undisclosed","stockexchange":"NYSE","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODIgdygCww","stockexchange_logokey":"$gCUzHIIl5WdaUySSBVfr4ukCJPjuwKJMFXjiY09JCLUNERZRom14T0","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$gCUzHIIl5WdaUySSBVfr4ukCJPjuwKJMFXjiY09JCLUNERZRom14T0","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":null,"valuationnumber":null}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"6/1959","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Taro Pharmaceutical Industries","logourl":"https://storage.googleapis.com/clean-finder-353810/$Q8m9BsUUHqutUA7RBUvmIR9ImevCZ0oEG5vj869zUarwynrtRc9SbO","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$Q8m9BsUUHqutUA7RBUvmIR9ImevCZ0oEG5vj869zUarwynrtRc9SbO","seoabout":"Taro Pharmaceutical Industries is a research-based international pharmaceutical company manufacturing topical dermatological products and developing a line...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":6,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Materials & Substances","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA","classificationName":"coretechnology"},{"depth":2,"name":"Raw Materials","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuMqZMJDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Patients","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","TechnologyClassificationModel>Materials & Substances#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA","TechnologyClassificationModel>Materials & Substances#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA>Raw Materials#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuMqZMJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Patients#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Materials & Substances#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA|2:>TechnologyClassificationModel>Materials & Substances#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA/Raw Materials#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuMqZMJDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Patients#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]},{"title":"Healthcare","key":"0-0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare","children":[{"title":"Patients","key":"0-0-1-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Patients"}]}]}],"coreTechnology":[{"title":"Materials & Substances","key":"0-0","path":"TechnologyClassificationModel>Materials & Substances","children":[{"title":"Raw Materials","key":"0-0-0","path":"TechnologyClassificationModel>Materials & Substances>Raw Materials"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Materials & Substances","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IfeyKYIDA","classificationName":"coretechnology"},{"depth":2,"name":"Raw Materials","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuMqZMJDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Patients","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drugs Discovery & Development"],"coreTechnology":["Materials & Substances","Raw Materials"],"targetCustomer":["Healthcare & Life Sciences","Life Sciences","Pharmaceuticals","Healthcare","Patients"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[{"id":"Skiy65EIIbq3nXz5QzoSWnmUMPZVkdwq5NDzpFMsX1XPwvLMsujpUk","date":"Jun 2024","amount":"Undisclosed","source":"https://www.prnewswire.com/news-releases/sun-pharma-completes-taro-merger-302180230.html","ticker":null,"eventtype":"DelistingEvent","valuation":"Undisclosed","investment":[],"capitalraised":"Undisclosed","stockexchange":"NYSE","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODIgdygCww","stockexchange_logokey":"$gCUzHIIl5WdaUySSBVfr4ukCJPjuwKJMFXjiY09JCLUNERZRom14T0","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$gCUzHIIl5WdaUySSBVfr4ukCJPjuwKJMFXjiY09JCLUNERZRom14T0","exit_label":"","po_label":"Public Offering","duetoacquisition":"","isdelisting":1,"acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":null,"valuationnumber":null},{"id":"t5XlZkxlKsdKG69lELpobxtXJkc3eZIOPqlbsp488dRcWVjFFWOVtt","date":"Jun 2024","amount":"$348M","source":"https://www.business-standard.com/companies/news/sun-pharma-completes-taro-merger-acquires-all-outstanding-shares-124062400760_1.html","mnatype":"Merger","eventtype":"MNAEvent","investment":[],"wasacquired":1,"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"acquiredcompany_mna":"Sun Pharma","acquiredcompany_mna_id":"HVHnVuoITlgYVXrTjJQpobCM6Z1ranbHPiJvPmRUMvaorlr2mB5Nxx","acquiredcompany_mna_type":"Multinational","acquiredcompany_mna_hidden":true,"acquiredcompany_mna_fullurl":"/mnc_page/sun-pharma","acquiredcompany_mna_logokey":"$f7bQHJVgU2m3GYrQtggBQn8TSKqZRkYVVpj9sD2uOcMRUcvOZtzvcN.png","acquiredcompany_mna_urlname":"/mnc_page/sun-pharma","acquiredcompany_mna_homepage":"http://sunpharma.com","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","acquiredcompany_mna_logourl":"https://storage.googleapis.com/clean-finder-353810/$f7bQHJVgU2m3GYrQtggBQn8TSKqZRkYVVpj9sD2uOcMRUcvOZtzvcN.png","exit_label":"","po_label":"Public Offering","acquireddesc":"Merged to","sectionname":"Public Offerings & Exit","amountnumber":348000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCI2vajCAw","date":"Mar 2012","amount":"Undisclosed","source":"","ticker":"TARO","eventtype":"POEvent","valuation":"Undisclosed","investment":[],"capitalraised":"Undisclosed","stockexchange":"NYSE","eventvisibility":"Public","amountvisibility":null,"fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODIgdygCww","stockexchange_logokey":"$gCUzHIIl5WdaUySSBVfr4ukCJPjuwKJMFXjiY09JCLUNERZRom14T0","style":"","hiddenCompanyTooltip":"","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$gCUzHIIl5WdaUySSBVfr4ukCJPjuwKJMFXjiY09JCLUNERZRom14T0","exit_label":"EXIT","po_label":"Initial Public Offering","acquireddesc":"Was acquired by","sectionname":"Public Offerings & Exit","amountnumber":null,"capitalraisednumber":null,"valuationnumber":null}],"privateequityfunding":[],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}